Document is current
Any future updates will be listed below
-
Authors
Speck, Rebecca M.
Harding, Gale
Chawla, Aarti R.
Agius, Christine R.
Bahadur, Shakeela W.
Hudson, Kathryn
Jaloudi, Mohammed A.
Parajuli, Ritesh
Vidal, Gregory A.
Bacci, Elizabeth D.
-
Funding
Funding for this research was provided by:
Eli Lilly and Company
- License Information
-
More Information
Article History
Received: 24 July 2025
Accepted: 21 November 2025
First Online: 4 December 2025
Declarations
:
: Athanasia Benekou of Evidera-PPD, a Thermo Fisher company, provided medical writing support, funded by Eli Lilly, in accordance with Good Publication Practice guidelines.
: The conduct of this study followed an institutional review board (IRB)-approved study protocol “Qualitative Interviews to Understand the Experience of Oral vs Intramuscular-administered Endocrine Therapy for Therapy for Breast Cancer: Patient and Healthcare Provider Perspectives” (Pro00073064), approved on August 3, 2023, by Advarra IRB. All eligible patients who agreed to participate provided electronic informed consent using DocuSign eSignature; eligible HCPs provided verbal consent.
: Rebecca M. Speck and Aarti R. Chawla are employees and hold stock in Eli Lilly and Company. Elizabeth D. Bacci and Gale Harding are employees of Evidera, which received payment from the study sponsor, Eli Lilly and Company, for work on this study. Kathryn Hudson advisory boards for Daiichi Sankyo and AstraZeneca. Ritesh Parajuli speakers bureaus for Merck and Gilead. Gregory A. Vidal—Consulting fees: Roche/Genentech, Novartis, Eli Lilly, Gilead, Puma, Pfizer, AstraZeneca, Hologic, Daiichi Sankyo, Concerto AI, Stemline, Merck, Arvinas, Myriad Genetics, Tersera; Fees for non-CME services: Eli Lilly, AstraZeneca, Gilead; Contracted research: Roche/Genentech, Puma, Celcuity, Merck, BMS, Eli Lilly, AstraZeneca, Pfizer, Gilead, GlaxoSmithKline, Novartis, Tesaro, Napo Pharmaceuticals, BioNtech. Christine R. Agius, Mohammed A. Jaloudi and Shakeela W. Bahadur have no competing interests.
